73 Villarruel-LpezA.Lpez-de la MoraD
[14] Glutathione has potent antioxidant properties
Diabetes Care, 28(1), 89-94
Comprender este perfil de efectos adversos es esencial para el manejo apropiado del tratamiento
, , 2
3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib (62)